CN114787342A - 扩增造血干细胞的小分子化合物及其组合 - Google Patents

扩增造血干细胞的小分子化合物及其组合 Download PDF

Info

Publication number
CN114787342A
CN114787342A CN202080086704.9A CN202080086704A CN114787342A CN 114787342 A CN114787342 A CN 114787342A CN 202080086704 A CN202080086704 A CN 202080086704A CN 114787342 A CN114787342 A CN 114787342A
Authority
CN
China
Prior art keywords
small molecule
cells
saha
hscs
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080086704.9A
Other languages
English (en)
Inventor
方日国
杨卉慧
史忠玉
袁鹏飞
于玲玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Ji Yin Medical Technology Co ltd
Original Assignee
Guangzhou Ji Yin Medical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Ji Yin Medical Technology Co ltd filed Critical Guangzhou Ji Yin Medical Technology Co ltd
Publication of CN114787342A publication Critical patent/CN114787342A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pain & Pain Management (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

提供了用于扩增造血干细胞(HSCs)的小分子抑制剂及其组合。所述小分子抑制剂及其组合均能够很好地促进造血干细胞(HSCs)的体外扩增，同时维持造血干细胞的干性。

Description

PCT国内申请，说明书已公开。

Claims (31)

  1. PCT国内申请，权利要求书已公开。
CN202080086704.9A 2019-12-16 2020-12-16 扩增造血干细胞的小分子化合物及其组合 Pending CN114787342A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/125687 2019-12-16
CN2019125687 2019-12-16
PCT/CN2020/136790 WO2021121266A1 (zh) 2019-12-16 2020-12-16 扩增造血干细胞的小分子化合物及其组合

Publications (1)

Publication Number Publication Date
CN114787342A true CN114787342A (zh) 2022-07-22

Family

ID=76478496

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080086704.9A Pending CN114787342A (zh) 2019-12-16 2020-12-16 扩增造血干细胞的小分子化合物及其组合

Country Status (9)

Country Link
US (1) US20230027247A1 (zh)
EP (1) EP4079842A4 (zh)
JP (1) JP2023507486A (zh)
KR (1) KR20220116508A (zh)
CN (1) CN114787342A (zh)
AU (1) AU2020404285A1 (zh)
CA (1) CA3162030A1 (zh)
TW (1) TW202136503A (zh)
WO (1) WO2021121266A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20212214A1 (es) 2019-04-15 2021-11-19 Edigene Inc Metodos y composiciones para editar acidos ribonucleicos (arn)
AU2020313143B2 (en) 2019-07-12 2024-04-04 Peking University Targeted RNA editing by leveraging endogenous adar using engineered RNAs
KR20230050123A (ko) * 2021-10-07 2023-04-14 삼성전자주식회사 전자 장치 및 그 제어 방법
WO2024200276A1 (en) * 2023-03-29 2024-10-03 Aarhus Universitet Heat-inactivated mesenchymal stem cells and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006298881A1 (en) * 2005-09-21 2007-04-12 4Sc Ag Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
WO2014189781A1 (en) * 2013-05-20 2014-11-27 Icahn School Of Medicine At Mount Sinai Enriched and expanded human cord blood stem cells for treatment of hematological disorders
CN104278008B (zh) * 2013-07-12 2020-08-21 北京宏冠再生医学科技有限公司 一种通过小分子化合物处理来制备多潜能干细胞的方法、试剂盒和用途
CN108060120B (zh) * 2016-11-07 2022-11-04 云南济慈再生医学研究院有限公司 用于分化的细胞重编程的小分子化合物组合、试剂盒及应用
IL273978B2 (en) * 2017-10-27 2024-09-01 Immunebridge Inc Preparations and methods for the production of expanded hematopoietic stem cells using fluorene annealing

Also Published As

Publication number Publication date
EP4079842A1 (en) 2022-10-26
US20230027247A1 (en) 2023-01-26
EP4079842A4 (en) 2024-01-24
CA3162030A1 (en) 2021-06-24
TW202136503A (zh) 2021-10-01
KR20220116508A (ko) 2022-08-23
WO2021121266A1 (zh) 2021-06-24
AU2020404285A1 (en) 2022-07-07
JP2023507486A (ja) 2023-02-22

Similar Documents

Publication Publication Date Title
CN114787342A (zh) 扩增造血干细胞的小分子化合物及其组合
CN112980789A (zh) 扩增造血干细胞的小分子化合物及其组合
To et al. A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells
EP0812201B1 (en) In vitro amplification of stem cells
WO2021149799A1 (ja) ヒト造血幹細胞などの血球系細胞を培養するために適した無血清培地および培養方法
JP2010509316A (ja) 末梢血管疾患を治療するためのエクスビボ培養された造血細胞の使用
Gupta et al. Hematopoiesis and stem cell renewal in long-term bone marrow cultures containing catalase
CN114075547A (zh) 扩增造血干细胞的方法及其组合物
Zimmerman et al. Large-scale selection of CD34+ peripheral blood progenitors and expansion of neutrophil precursors for clinical applications
EP1807509A1 (en) Multipotent stem cells isolated from umbilical cord blood and the cellular therapeutic agent comprisin the same for treating ischemic disease
JP2024128116A (ja) 細胞群及びその取得方法
CN110551688B (zh) 一种诱导体细胞重编程为造血干/祖细胞且促进造血干/祖细胞体外扩增的组合物及其应用
WO2022143675A1 (zh) 用于扩增并维持HSCs自我更新能力和分化潜能的培养基组合物及其应用
EP4219691A1 (en) Use of compound for improving transplantation efficiency of human hematopoietic stem cells
KR101132858B1 (ko) 내피전구세포의 체외 증폭방법
CN110804591B (zh) 含聚合物微纳小球的造血干细胞体外培养体系及应用
KR100999905B1 (ko) 생착능이 증가된 조혈줄기세포의 제조방법
Hall The Characterization of Hematopoiesis in Murine Fetal Bone Marrow
Pranke et al. Stem Cells from Umbilical Cord Blood
JP2022017977A (ja) 細胞、組成物及び治療用組成物
KR20240147932A (ko) 적혈구 및 혈소판의 제조 방법
KR101149007B1 (ko) 생착능이 증가된 조혈줄기세포의 제조방법
WO2024018018A1 (fr) Utilisation d'un composé vitisine pour la production de cellules hématopoïétiques
Massenkeil et al. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-vs.-host disease after allogeneic stem cell transplantation
Schröder et al. GMP Compliant Expansion of Hematopoietic Stem Cells (CD34+) Selected from Cord Blood for a Phase I Cell Therapy Trial

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination